Development, Commercialization and Supply Agreements - Additional Information (Detail)	1 Months Ended								3 Months Ended		12 Months Ended
	Jan. 31, 2022 USD ($)	Jan. 31, 2021 USD ($)	Feb. 29, 2020 USD ($)	Jan. 31, 2020 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Mar. 31, 2016 USD ($)	Feb. 28, 2015 USD ($)	Mar. 31, 2022 USD ($) Item	Mar. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2020 USD ($)
License And Collaboration Agreements [Line Items]
Revenue recognized related to upfront and milestone payments									$ 372,000	$ 662,000
Licenses revenue									94,630,000	142,170,000
Deferred revenue									16,337,000	17,970,000	$ 16,709,000		$ 18,632,000
Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue									$ 93,986,000	141,383,000
Mochida | In-licenses
License And Collaboration Agreements [Line Items]
Milestones payment	$ 1,000,000.0	$ 1,000,000.0
Mochida | In-licenses | Research and Development Expense
License And Collaboration Agreements [Line Items]
Upfront payment												$ 2,700,000
Edding | Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable up-front received								$ 15,000,000.0
Number of indications of the regulatory milestone events relating to the submission and approval | Item									3
Amounts to be received upon achievement of the regulatory milestone events									$ 33,000,000.0
Sales-based milestone event payment									120,000,000.0
Revenue recognized related to upfront and milestone payments									200,000	300,000
Deferred revenue									9,600,000		9,800,000
Edding | Out-licenses | Licensing Revenue
License And Collaboration Agreements [Line Items]
Licenses revenue									7,300,000		7,100,000
Edding | Out-licenses | Maximum
License And Collaboration Agreements [Line Items]
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone									153,000,000.0
Amounts to be received upon achievement of the regulatory milestone events									15,000,000.0
Sales-based milestone event payment									50,000,000.0
Edding | Out-licenses | Minimum
License And Collaboration Agreements [Line Items]
Amounts to be received upon achievement of the regulatory milestone events									2,000,000.0
Sales-based milestone event payment									5,000,000.0
Edding | Out-licenses | Clinical Trial Application
License And Collaboration Agreements [Line Items]
Non-refundable milestone payment received							$ 1,000,000.0
Biologix FZCo | Out-licenses
License And Collaboration Agreements [Line Items]
Revenue recognition period of non-refundable up-front payment							10 years
Biologix FZCo | Out-licenses | Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue									0	500,000
HLS | Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable up-front received						$ 5,000,000.0
Revenue recognized related to upfront and milestone payments									100,000	$ 300,000
Deferred revenue									6,100,000		6,200,000
Non-refundable up-front received period						6 months
Non-refundable milestone payment received			$ 2,500,000	$ 3,800,000	$ 2,500,000	$ 2,500,000
Non-refundable milestone payment received						3,800,000
HLS | Out-licenses | Health Canada
License And Collaboration Agreements [Line Items]
Non-refundable milestone payment received						2,500,000
HLS | Out-licenses | Licensing Revenue
License And Collaboration Agreements [Line Items]
Licenses revenue									$ 7,600,000		$ 7,500,000
HLS | Out-licenses | Maximum
License And Collaboration Agreements [Line Items]
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone						$ 50,000,000.0